129 related articles for article (PubMed ID: 21630531)
21. Size Matters and How You Measure It: A Gram-Negative Antibacterial Example Exceeding Typical Molecular Weight Limits.
Ruggiu F; Yang S; Simmons RL; Casarez A; Jones AK; Li C; Jansen JM; Moser HE; Dean CR; Reck F; Lindvall M
ACS Infect Dis; 2019 Oct; 5(10):1688-1692. PubMed ID: 31478369
[TBL] [Abstract][Full Text] [Related]
22. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms.
Livermore DM; Mushtaq S; Warner M
J Antimicrob Chemother; 2010 Nov; 65(11):2382-95. PubMed ID: 20846937
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activities of p-toluenesulfonyl-hydrazinothiazoles and hydrazinoselenazoles against multi-drug resistant Gram-negative phenotypes.
Mbaveng AT; Ignat AG; Ngameni B; Zaharia V; Ngadjui BT; Kuete V
BMC Pharmacol Toxicol; 2016 Jan; 17():3. PubMed ID: 26782344
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ABT773, a new ketolide derivative exhibiting innovative microbiological properties against well-characterised antibiotic resistant pathogens in Italy.
Bozzolasco M; Debbia EA; Roveta S; Schito AM; Marchese A
Int J Antimicrob Agents; 2004 Jan; 23(1):11-6. PubMed ID: 14732308
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antimicrobial properties of substituted 3-aminoxypropionyl and 3-aminoxy-(E)-2-methoxyiminopropionyl monobactams.
Balsamo A; Macchia B; Orlandini E; Rossello A; Macchia F; Broccali G; Fonio W
Farmaco; 1990 Jul; 45(7-8):879-88. PubMed ID: 2282121
[TBL] [Abstract][Full Text] [Related]
26. Naphthylthiazoles: Targeting Multidrug-Resistant and Intracellular Staphylococcus aureus with Biofilm Disruption Activity.
Hagras M; Abutaleb NS; Ali AO; Abdel-Aleem JA; Elsebaei MM; Seleem MN; Mayhoub AS
ACS Infect Dis; 2018 Dec; 4(12):1679-1691. PubMed ID: 30247876
[TBL] [Abstract][Full Text] [Related]
27. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?
Falagas ME; Mavroudis AD; Vardakas KZ
Expert Rev Anti Infect Ther; 2016 Aug; 14(8):747-63. PubMed ID: 27400643
[TBL] [Abstract][Full Text] [Related]
28. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections.
Gomila A; Shaw E; Carratalà J; Leibovici L; Tebé C; Wiegand I; Vallejo-Torres L; Vigo JM; Morris S; Stoddart M; Grier S; Vank C; Cuperus N; Van den Heuvel L; Eliakim-Raz N; Vuong C; MacGowan A; Addy I; Pujol M;
Antimicrob Resist Infect Control; 2018; 7():111. PubMed ID: 30220999
[TBL] [Abstract][Full Text] [Related]
29. Discovery and structure-activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors.
Cooper IR; McCarroll AJ; McGarry D; Kirkham J; Pichowicz M; Walker R; Warrilow C; Salisbury AM; Savage VJ; Moyo E; Forward H; Cheung J; Metzger R; Gault Z; Nelson G; Hughes D; Cao S; Maclean J; Charrier C; Craighead M; Best S; Stokes NR; Ratcliffe AJ
Bioorg Med Chem Lett; 2016 Sep; 26(17):4179-83. PubMed ID: 27499455
[TBL] [Abstract][Full Text] [Related]
30. Azetidinone-isothiazolidinones: stereoselective synthesis and antibacterial evaluation of new monocyclic beta-lactams.
Cerić H; Sindler-Kulyk M; Kovacević M; Perić M; Zivković A
Bioorg Med Chem; 2010 May; 18(9):3053-8. PubMed ID: 20382539
[TBL] [Abstract][Full Text] [Related]
31. Monobactam formation in sulfazecin by a nonribosomal peptide synthetase thioesterase.
Oliver RA; Li R; Townsend CA
Nat Chem Biol; 2018 Jan; 14(1):5-7. PubMed ID: 29155429
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and pharmacological evaluation of some novel 2-(5-hydroxy-5-trifluoromethyl-4,5-dihydropyrazol-1-yl)-4-(coumarin-3-yl)thiazoles.
Aggarwal R; Kumar S; Kaushik P; Kaushik D; Gupta GK
Eur J Med Chem; 2013 Apr; 62():508-14. PubMed ID: 23416192
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial and β-Lactamase Inhibitory Activity of Monocyclic β-Lactams.
Decuyper L; Jukič M; Sosič I; Žula A; D'hooghe M; Gobec S
Med Res Rev; 2018 Mar; 38(2):426-503. PubMed ID: 28815732
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antibacterial activity of C-4 thio- and dithiocarbamate monobactam derivatives.
Cascio G; Lorenzi L; Caglio D; Manghisi E; Arcamone F; Guanti G; Satta G; Morandotti G; Sperning R
Farmaco; 1996 Mar; 51(3):189-96. PubMed ID: 8688141
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria.
Tang SS; Apisarnthanarak A; Hsu LY
Adv Drug Deliv Rev; 2014 Nov; 78():3-13. PubMed ID: 25134490
[TBL] [Abstract][Full Text] [Related]
36. Intravenous colistimethate for multidrug-resistant Gram-negative bacteria.
Zavascki AP; Li J
Lancet Infect Dis; 2008 Jul; 8(7):403-5. PubMed ID: 18582831
[No Abstract] [Full Text] [Related]
37. Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
Koulenti D; Song A; Ellingboe A; Abdul-Aziz MH; Harris P; Gavey E; Lipman J
Int J Antimicrob Agents; 2019 Mar; 53(3):211-224. PubMed ID: 30394301
[TBL] [Abstract][Full Text] [Related]
38. New β-lactam antibiotics and β-lactamase inhibitors.
Bush K; Macielag MJ
Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
[TBL] [Abstract][Full Text] [Related]
39. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
40. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: beta-lactams in peril!
Thomson JM; Bonomo RA
Curr Opin Microbiol; 2005 Oct; 8(5):518-24. PubMed ID: 16126451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
